The interactions between the nervous and immune systems have been recognized in the development of neurodegenerative disease. This can be exploited through detection of the immune response to autoantigens in assessing the neurotoxicity of environmental chemicals. To test this hypothesis, the following questions were addressed. a) Are autoantibodies to nervous system (NS) antigens detected in populations exposed to environmental or occupational chemicals? In sera of male workers exposed to lead or mercury, autoantibodies, primarily IgG, to neuronal cytoskeletal proteins, neurofilaments (NFs), and myelin basic protein (MBP) were prevalent. These findings were confirmed in mice and rats exposed to either metal. b) Do autoantibodies to NS antigens relate to indices of exposure? In humans exposed to either metal, and similarly in exposed rats, titers of lgG against NFs and MBP significantly correlated with blood lead or urinary mercury, the typical indices of exposure. c) Do autoantibodies correlate with sensorimotor deficits? In workers exposed to lead or mercury, a significant correlation was observed between lgG titers and subclinical deficits. Doses of metals used in rat exposures were subclinical, suggesting that autoantibodies may be predictive of neurotoxicity. d) Is the detection indicative of nervous system pathology? In rats exposed to metals, histopathology indicated central nervous system (CNS) and peripheral nervous system (PNS) damage. In addition there was evidence of astrogliosis, which is indicative of neuronal damage in the CNS, and the presence of lgG concentrated along the blood-brain barrier, as indicated by immunostaining for antibodies. e) Are immune responses to NS antigens pathogenic? Immunoglobulin fractions from rat and human sera interfered with neuromuscular function. These studies suggest that the detection of autoantibodies to NS-specific antigens may be used to monitor the development of neurotoxicity to environmental chemicals and that immune mechanisms may be involved in the progression of neurodegeneration.
The inaccessibility of the nervous system has long posed a challenge to neuroscientists and in particular to neurotoxicologists. This inaccessibility has impeded the evaluation of cellular and molecular changes associated with the initial changes of neurotoxicity, prior to overt clinical deficits in live animals and humans. Current methods of assessing the development of and recovery from neurotoxic insult include behavioral, electrophysiologic, and brain imaging techniques (1, 2) . However, these evaluations require highly trained personnel, are costly, and do not identify specific cellular substrates or mechanisms. This imposes limitations to their utility in clinical diagnostics, risk assessment, and their applicability to populations in the exposure arena (e.g., agriculture, industry). Furthermore, the detection of deficits often does not occur in the absence of overt manifestations.
O'Callaghan (3, 4) has proposed that neurotypic and gliotypic proteins be used to detect and characterize the cellular response to toxicant-induced injury. Alterations in nervous system-specific proteins; for example, glial fibrillary acidic protein (GFAP), the astrocytic intermediate filament, may be expressed at low exposure levels of neurotoxic metals and toluene (3, (5) (6) (7) and other nervous system insults. This reactive gliosis occurs secondary to neuronal insult and degeneration. Although direct measurement of proteins in the brain may provide valuable insights into the cellular targets of neurotoxicity in animal studies (3, 8, 9) , they are not applicable to human populations. However, this evidence should prove invaluable in evaluating potential biomarkers of neurotoxicity.
We have proposed that exposure to neurotoxic agents and the attendant neurodegeneration with the liberation of neural proteins can induce an autoimmune response conveniently measurable in blood. This immune response is reflected in the production of serum autoantibodies against nervous system proteins and activation of lymphocytes. Surprisingly, few neurotoxicology studies have investigated the possible involvement of the immune system and autoimmunity as a marker or as an effector in the development of neurotoxicity.
Neurocytology, Immunology, and Immunoprivilege
It is well established that the nervous system comprises the heterogeneous cell populations.
Neurons, the excitable elements of the nervous system, are considered synonymous with nervous system function. These are the cells responsible for detecting intrinsic and extrinsic environmental stimuli (sensory function), communicating these stimuli for interpretation (brain and spinal cord function), and formulating appropriate responses to these stimuli (motor function). Despite their being the minority cells of the nervous system, neurons control and regulate body function, thus placing them in a unique position of vulnerability. Neuroglia, astrocytes, oligodendrocytes, Schwann cells, and microglia are the majority cells. Functionally they provide protection, influencing electrical conductive properties of the neuronal axons and dendrites. Astrocytes, Schwann cells, and central macrophages (microglia), however, may play a role in immune activation within the nervous system.
Astrocytes may play a role in the regulation of inflammation and immune responses in the central nervous system (10) . Astrocytes release interleukin (IL)-1 in response to substance P stimulation (11) and produce tumor necrosis factor (TNF)-oc in response to viral infection (12, 13) and bacterial lipopolysaccharide (LPS) (14) . Viral or LPS stimulation induce the gene expression of IL-la; IL-11; IL-6, and interferon (IFN)-y by astrocytes (12) . Astrocytes also secrete IL-3, which induces microglial proliferation (15, 16) , suggesting a cooperative role between astrocytes and microglia during cell injury. Astrocytes also produce complement factors C3 and B (17) . Astrocytes not only produce cytokines and complement factors but also respond to cytokine stimulation. Human astrocytes proliferate in response to TNF-a. This is accompanied by downregulation of GFAP expression (18). Stimulation of murine and human astrocytes by IFN-y enhances their expression of class II major histocompatibility complex (MHC) (19, 20) . Astrogliosis, the astrocytic proliferative response to neuronal injury, may be in response to IFN-y (21), whereas it is downregulated by IL-4 (22).
Although astrocytes may not act as the major antigen-presenting cells (APCs), microglia act as APCs in the brain. These are among the first cells to be recruited in response to injury (23). In turn, microglia may stimulate astrocytes following injury through the production of TNF-a, IL-1 , and IL-6 (23,24-26). The proliferation and APC activity of microglia has been shown to be stimulated by IFN-y, colony-stimulating factor of macrophages (16, 27, 28 (33, 34) .
Under normal circumstances, the nervous systems, both central and peripheral, are considered relatively immunoprivileged, as provided by the blood-brain barrier (BBB) and blood-nerve barrier (BNB). The BBB consists of specialized endothelial cells with tight junctions, pericytes, and bone marrowderived perivascular elements. These are enclosed within a basal lamina and astrocyte foot processes (35) . On the other hand, the BNB is formed by the permeable epineurium, the tight junctions of the perineurium, and the impermeable endoneurium (35 (10, 40 (49) , Guillain-Barre syndrome (50) , and experimental allergic encephalomyelitis (51) . The nervous system itself may have immunologic functions as noted earlier (36, 52 (90) . Lead also enhances the production and release of IL-2 from T lymphocytes (91), thus enhancing B-cell responsiveness (90) . These observations have led to the suggestion that lead exposure may result in an autoimmune response (90) .
Highly relevant to the presence of autoantibodies are studies indicating that low levels of lead enhance immunoglobulin synthesis (86, 92 In the nervous system, astrocytes act as sites of deposition for heavy metals, including mercury (96, 97) and lead (98, 99) , where these metals may modulate metabolic function (100, 101) . In this regard, astrocytes may themselves be targets of lead and mercury, resulting in their degeneration and death, whether as a primary target or secondary to astrogliosis (102) (103) (104) (105) (106) . Similarly, other chemicals may induce damage to glia. Pilocarpine-induced epilepsy in rats resulted in glial damage within the substantia nigra and basal cortex (107) . Recently, toluene inhalation has been reported to result in a reduction in the astrocyte-specific protein GFAP (7) . Additionally, some chemicals may induce a vasculopathy, resulting in leakage of barriers. Inorganic lead and cadmium fall within this category (94) .
On the basis of this classification, we propose that detection of immune responses to autoantigens characteristic of different target sites may be used in identifying the effects and specific targets of the neurotoxic chemicals. Coupled with neuropathologic assessment, these autoimmune responses can be validated for experimental animal studies and the monitoring of human populations. A summary of potential cellular targets and cellular antigens in the nervous system is presented in Figure 1 . Additional nervous system-specific proteins are discussed by O'Callaghan (4) and Linington and Brostoff (107) .
Autoantibodies as Markers of Nervous System Injury: Rationale and Hypothesis
In our use of the term marker or biomarker, a distinction is made here between markers of exposure and markers of effect. For example, blood lead levels are used to indicate exposure to lead; they do not provide information on the neurotoxicity of lead. It is inferred from historical human and animal studies that a particular blood level is associated with certain symptoms or lesion. Furthermore, this inference is often based on detection of overt toxicity but does not delineate changes that may be early predictors of toxicity. A second distinction is also made here. In the study of the link between environmental chemicals, autoimmunity, and the nervous system, we distinguish between the concept of immunologic biomarkers of neurotoxicity, immune mechanisms of neurotoxicity, and the immunotoxic effects of environmental chemicals. The latter is discussed in other reviews. The concept of using immunologic indicators to reflect environmental exposure-induced damage to other systems derives from the definition of the immune system as a Figure 1 . Potential targets and autoantigens to which autoantibodies may be detected as a result of neurotoxicity. Abbreviations: ChAT, choline acetyltransferase; CNS, central nervous system; MAPs, microtubule-associated proteins; MT, microtube; NFs, neurofilament triplet proteins; PNS, peripheral nervous system. (1) Structural proteins of the neuron such as the NFs, a-and P-tubulin of the MT, and MAPs. (2) Proteins of neurotransmission such as sodium, potassium, and calcium channels or those associated with the vesicle-docking fusion essential for neurotransmitters release (e.g., synaptophysin, synapsin, synaptotagmin, latrototoxin receptor), or intracellular neurotransmitter synthesizing enzymes (e.g., ChAT). (3) Proteins of the postsynaptic targets: neurons/muscle (e.g., neurotransmitter receptors, actin, myosin, desmin) or catabolic enzymes (e.g., acetylcholinesterase). (4) Proteins of myelin and myelinating cells such as myelin basic protein and myelin-associated glycoprotein, common to both the CNS and the PNS, or proteolipid protein, found only in CNS myelin. PO and peripheral myelin protein-22 of peripheral myelin. (5) Proteins associated with astroglia of the CNS or the blood-brain barrier, such as glial fibrillary acidic protein, S-100, and vimentin (in developmental studies). Furthermore, although some neuronal proteins are widely distributed throughout the nervous system, others are restricted to only certain neurons or brain regions (G-substrate in the cerebellum, DARPP-32 in the neostriatum, and SNAP-25 in the hippocampus). Proteins of the CNS and PNS are reviewed in (4) and (107) . functional system responsible for surveillance of the host's various organ systems. The immune system provides a unique opportunity for the neurotoxicologist, particularly in the reduction in the number of experimental animals and in clinical toxicology, for assessing the pathologic status of other systems. This is facilitated by the relatively noninvasive sampling and collection of sera and immune cells. Although this approach has been used successfully by toxicologists in the study of other systems [reviewed in (108) (109) (110) (111) (112) ], a review of the literature reveals a paucity of studies dealing with neurotoxic exposures and autoimmune responses (113) .
The generation of autoantibodies to nervous system-specific antigens is feasible in the presence of neuronal death, axonal degeneration, demyelination, and glial death such as that precipitated by neurotoxic agents in the CNS or PNS. This exposes and liberates intracellular antigens, often sequestered antigens that the immune system has not encountered previously. Our hypothesis is summarized in Figure 2 . Proteins specific to nervous system structures would be presented as autoantigens by resident microglia in the CNS or as infiltrating macrophages in the PNS. This would result in a cellular and/or humoral response with autoantibodies raised against these autoantigens in the latter case. The generation of these autoantibodies would likely occur, particularly with metal intoxication, in light of their ability to compromise blood barriers (103, 104, 114, 115) . In this way, the immune system provides a means whereby cellular damage in the nervous system can be documented and measured in serum, thereby eliminating the problems associated with the inaccessibility of the nervous system.
Autoantibodies in Humans and Animals Exposed to Neurotoxic Agents
The use of autoantibody detection to indicate nervous system insult was tested in our laboratory in several populations and verified in animal studies (Table 1) . To illustrate the utility of these assays, we will concentrate on results obtained from inorganic lead exposures.
Autoantibodies and Exposure
Field testing of autoantibody assays was performed by our laboratory in male workers occupationally exposed to lead at a battery factory (blood lead: 10-40 pg/dL) or mercury vapor (urinary mercury: 6-30 ,ug/g creatine) at a fluorescent light factory. In addition, a reference group from a frozen food packing plant with no prior work history of exposure to either metal was also recruited (116) (117) (118) Table 2 ).
confirmed (119, 121 Figure 4 . The early detection of IgM is consistent with a primary antigen challenge (in this case autoantigens). There was significant elevation of IgM titers, followed by a gradual isotype switching to IgG at later durations. In both human and rat studies, autoantibody levels, particularly anti-NFs, correlated significantly with blood lead-the index of exposure for both humans and rats (Table 2) .
To confirm the presence of autoreactive B lymphocytes expressing autoantibodies to nervous system proteins, splenocyte preparations from lead-exposed rats and mice (123) were challenged with LPS. Both IgM and IgG against NFs, GFAP, and MBP were detected in the splenic supernatants. Figure 5 shows the 1gM response of LPS-stimulated rat splenic cells at 7 days of exposure. In mice the production of autoantibodies from splenocytes was accompanied by IL-6 and IL-2 production by T lymphocytes (concanavalin A-stimulated cultures). IL-6 is believed to stimulate B-lymphocyte differentiation to antibody-producing plasma cells and copromotes IL-2 production by mature T lymphocytes. IL-2 promotes secretion of antibodies from activated B lymphocytes and is consistent with Th-assisted B-cell responses (102) .
Autoantibodies and Clinical Deficits
In exposed human populations, antibody titers that significantly correlated with exposure and sensorimotor function were predominantly IgG. IgG is the isotype most commonly associated with secondary antigen challenge or antigen persistence and pathology (124) . A significant dose-response relationship between the total number of detectable autoantibodies of the G isotype (IgG score) to the five antigen proteins and the total number of upper and lower limb sensorimotor deficits (clinical score) was observed ( Figure 6 ). This suggests an association between the appearance of antibodies in the sera and the neurotoxicity of metal exposure. However, it must be emphasized that sensorimotor deficits were subclinical and not overt.
Antibodies and Cellular Targets
The neuropathology associated with chronic exposures to mercury or lead primarily involves the neuroaxon with secondary demyelination (105, 115, 125) . In the human studies, anti-NFs, IgG isotype, were the most frequently detected antibodies. These were also the antibodies and the isotype best correlated with blood lead or urinary mercury and clinical scores of sensorimotor deficits. This is consistent with the type of neuropathy in humans that manifests primarily neuroaxonal damage. Furthermore, the detection of anti-GFAP titers in these studies supports the targeting of the CNS and astrocytes by heavy metals (96) (97) (98) , since astrocytes are exclusively found in the CNS. In this manner, autoantibodies may provide a means whereby subcellular targets and the progression of neuropathy may be documented.
In this context the temporal appearance of autoantibodies in serum provides information on the extent of target cell involvement and the progression of insult. For example, it is likely that anti-NF titers would be the first to appear with primary neuronal involvement (e.g., mercury), whereas anti-MBP would precede all others in the case of primary demyelination (triethyltin).
Toxic Exposures May Precipitate Autoimmunity by Altering Antigen Immunogenicity
The role of environmental factors in the production or augmentation of autoimmune responses has been suggested for some time. The interaction of drugs or environmental chemicals, including metals (e.g., gold, mercury, and glomerulonephritis), with endogenous protein constituents may alter their immunogenicity and result in the induction of immune responses reflected in the generation of autoantibodies (108) . Having detected Table 2 . Correlation (r) and significance level (p) between autoantibody titers and blood lead in workers occupationally exposed to lead and rats experimentally exposed to lead in the drinking water.
Anti-NF-68
Anti-NF-160 (130) (131) (132) .
We have shown that the immunoglobulin fragment from lead-exposed rats attenuates presynaptic neurotransmission in isolated neuromuscular preparations ( Figure 7 ) (133 (139) . Lead blocks different types of channels (140, 141) and interferes with calcium regulatory proteins such as protein kinase C and calmodulin (142, 143 (167) . The blood-testes barrier is believed to serve a function similar to that of the BBB and may be affected by metals.
In addition to the above-described studies, autoantibodies to nervous system proteins have been detected in animals exposed to other inorganic and organic metals or solvents and in humans exposed to metals or pesticides (172-174).
Conclusions and Recommendations
The studies discussed in this review illustrate the utility of the immune system's functional status for developing markers of neurotoxic effects of chemicals. They also suggest a role of environmental chemicals in the development of nervous system autoimmune disease and/or the progression of neuropathy. In the case of the autoantibody assays, these studies suggest a promising association between the appearance of autoantibody titers against nervous system proteins and exposure to subclinical levels of known neurotoxicants 
